Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 175.71% vs 27.93% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is -2.56% vs -36.25% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 11.78% vs 7.15% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -178.29% vs 69.93% in Mar 2024
Compare Profit and Loss Results of Oxygenta Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
109.00
134.00
-25.00
-18.66%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
109.00
134.00
-25.00
-18.66%
Expenditure (Ex Depriciation)
Stock Adjustments
-3.00
-1.00
-2.00
-200.00%
Raw Materials Consumed
100.00
54.00
46.00
85.19%
Power & Fuel Cost
6.00
3.00
3.00
100.00%
Employee Cost
6.00
34.00
-28.00
-82.35%
Operating Expenses
5.00
5.00
0.00
0.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
4.00
-4.00
-100.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
1.00
-1.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
119.00
116.00
3.00
2.59%
Operating Profit (PBDIT) excl Other Income
-9.00
17.00
-26.00
-152.94%
Other Income
1.00
2.00
-1.00
-50.00%
Operating Profit (PBDIT)
-8.00
20.00
-28.00
-140.00%
Interest
1.00
2.00
-1.00
-50.00%
Profit before Depriciation and Tax
-10.00
17.00
-27.00
-158.82%
Depreciation
0.00
6.00
-6.00
-100.00%
Profit Before Taxation & Exceptional Items
-11.00
11.00
-22.00
-200.00%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
-11.00
11.00
-22.00
-200.00%
Provision for Tax
-1.00
3.00
-4.00
-133.33%
Profit After Tax
-9.00
8.00
-17.00
-212.50%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
-63.00
-103.00
40.00
38.83%
Profit Available for appropriations
-73.00
-95.00
22.00
23.16%
Appropriations
-73.00
-95.00
22.00
23.16%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
-2.69
2.28
-4.97
-217.98%
Profit And Loss - Net Sales
Net Sales 109.30 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 175.71% vs 27.93% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) -9.94 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -2.56% vs -36.25% in Mar 2024
Profit And Loss - Interest
Interest 1.78 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 11.78% vs 7.15% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax -9.68 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -178.29% vs 69.93% in Mar 2024
